Novel CHK1 inhibitor MU380 exhibits significant single-agent activity in TP53-mutated chronic lymphocytic leukemia cells

HAEMATOLOGICA

Boudny, M; Zemanova, J; Khirsariya, P; Borsky, M; Verner, J; Cerna, J; Oltova, A; Seda, V; Mraz, M; Jaros, J; Jaskova, Z; Spunarova, M; Brychtova, Y; Soucek, K; Drapela, S; Kasparkova, M; Mayer, J; Paruch, K; Trbusek, M, 2019: Novel CHK1 inhibitor MU380 exhibits significant single-agent activity in TP53-mutated chronic lymphocytic leukemia cells. HAEMATOLOGICA 104(12), p. 2443 - 2455, doi: 10.3324/haematol.2018.203430

Research Groups:

Microenvironment of Immune Cells

CEITEC authors:

Václav Šeda, Ph.D.
Prof. Marek Mráz, Ph.D.